Life Science News

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") will release its fourth-quarter and full-year 2021 financial results on Wednesday, Feb. 23, 2022 . Bausch Health will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Conference Call Details

Date:

Wednesday, Feb. 23, 2022



Time:

8:00 a.m. ET



Webcast:

http://ir.bauschhealth.com/events-and-presentations



Participant Event Dial-in:

+1 (888) 317-6003 (United States)

+1 (412) 317-6061 (International)

+1 (866) 284-3684 (Canada)



Participant Passcode:

3503759



Replay Dial-in:

+1 (877) 344-7529 (United States)

+1 (412) 317-0088 (International)

+1 (855) 669-9658 (Canada)



Replay Passcode:

8454801 (replay available until March 2, 2022)

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 856-3855

(908) 927-1198

(877) 281-6642 (toll free)


Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch-health-companies-inc-will-release-fourth-quarter-and-full-year-2021-financial-results-on-february-23-301474436.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

BHC:CA,BHC

Medtronic to announce financial results for its fourth quarter and full fiscal year 2022

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2022, which ended on Friday, April 29, 2022 .

Medtronic will host a video webcast at 7:00 a.m. CDT on Thursday , May 26, 2022, to discuss financial results for its fourth quarter and full fiscal year 2022. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

  • Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life
  • Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies
  • One-year outcomes for Navitor™ transcatheter aortic valve implantation (TAVI) system show the safety and effectiveness of this therapy and durable performance of the sealing cuff in minimizing paravalvular leak for patients with severe aortic stenosis

Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company's latest-generation transcatheter aortic valve implantation (TAVI) system. The company also showcased new data for MitraClip™ and Amplatzer™ Amulet™, two key components of the company's industry-leading structural heart portfolio.

All data were presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held in Paris from May 17-20, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on May 18, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on July 15, 2022, to shareholders of record as of June 15, 2022.

About Thermo Fisher Scientific

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Premier Health Reports FY2022 Second Quarter Results

Premier Health Reports FY2022 Second Quarter Results

Premier Health of America Inc. (TSXV: PHA ) (the " Corporation "), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and Management Discussion and Analysis for its second quarter ended March 31, 2022.

Summary

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU ® Research Posters Will Be Presented

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, today announced seven posters on behalf of XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), will be shared at Digestive Disease Week® (DDW) 2022 which is being held virtually and in-person in San Diego, Calif. from May 21-24, 2022 . The posters will be accessible on DDW's ePoster's website beginning Saturday, May 21, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17, 2022.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×